文献速递临床试验与 GCP真实世界研究与卫生经济

比较增强版接纳承诺疗法联合常规善后照护与仅常规善后照护在癌症生存者中的实用性随机对照试验研究方案:癌症后生存者康复评估(SURECAN)试验

Study protocol for a pragmatic randomised controlled trial of comparing enhanced acceptance and commitment therapy plus (+) added to usual aftercare versus usual aftercare only, in patients living with or beyond cancer: SUrvivors' Rehabilitation Evaluation after CANcer (SURECAN) trial.
PubMed 文献 · Trials · 2024-04-02

本研究为多中心、实用性、理论驱动的随机对照试验,计划招募344例完成根治性治疗且生活质量低的癌症生存者,按1:1随机分配至ACT+联合常规善后照护组或仅常规善后照护组,主要结局为52周时FACT-G量表测量的生活质量,并评估成本效果。

要点

  • ACT+包括基于接纳承诺疗法的干预,整合体育活动和重返工作/职业支持选项。
  • 干预由NHS谈话治疗、专科服务和癌症慈善机构提供,最多8次会话,可面谈、电话或Skype进行。
  • 主要结局为52周时FACT-G测量的生活质量,同时评估成本效果。

核心结论

  • 本研究旨在评估ACT+联合常规善后照护是否比仅常规善后照护更有效且更具成本效果。

研究设计与样本

  • 多中心、实用性、理论驱动的随机对照试验,计划招募344例来自二级照护机构、已完成根治性癌症治疗且FACT-G评估生活质量低的参与者,按1:1随机分配。

主要发现

  • 原文未报告研究结果。

关键数值与推荐

  • 主要结局为52周时使用功能癌症治疗评估-通用量表(FACT-G)测量的生活质量。
  • 干预组接受ACT+联合常规善后照护,对照组仅接受常规善后照护。
  • 干预ACT+最多8次会话,每周或每两周一次,采用面谈、电话或Skype等不同方式。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Two million people in the UK are living with or beyond cancer and a third of them report poor quality of life (QoL) due to problems such as fatigue, fear of cancer recurrence, and concerns about returning to work. We aimed to develop and evaluate an intervention based on acceptance and commitment therapy (ACT), suited to address the concerns of cancer survivors and in improving their QoL. We also recognise the importance of exercise and vocational activity on QoL and therefore will integrate options for physical activity and return to work/vocational support, thus ACT Plus (+). METHODS: We will conduct a multi-centre, pragmatic, theory driven, randomised controlled trial. We will assess whether ACT+ including usual aftercare (intervention) is more effective and cost-effective than usual aftercare alone (control). The primary outcome is QoL of participants living with or beyond cancer measured using the Functional Assessment of Cancer Therapy: General scale (FACT-G) at 52 weeks. We will recruit 344 participants identified from secondary care sites who have completed hospital-based treatment for cancer with curative intent, with low QoL (determined by the FACT-G) and randomise with an allocation ratio of 1:1 to the intervention or control. The intervention (ACT+) will be delivered by NHS Talking Therapies, specialist services, and cancer charities. The intervention consists of up to eight sessions at weekly or fortnightly intervals using different modalities of delivery to suit individual needs, i.e. face-to-face sessions, over the phone or skype. DISCUSSION: To date, there have been no robust trials reporting both clinical and cost-effectiveness of an ACT based intervention for people with low QoL after curative cancer treatment in the UK. We will provide high quality evidence of the effectiveness and cost-effectiveness of adding ACT+ to usual aftercare provided by the NHS. If shown to be effective and cost-effective then commissioners, providers and cancer charities will know how to improve QoL in cancer survivors and their families. TRIAL REGISTRATION: ISRCTN: ISRCTN67900293 . Registered on 09 December 2019. All items from the World Health Organization Trial Registration Data Set for this protocol can be found in Additional file 2 Table S1.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Khan I, Taylor SJC, Robinson C, et al. Study protocol for a pragmatic randomised controlled trial of comparing enhanced acceptance and commitment therapy plus (+) added to usual aftercare versus usual aftercare only, in patients living with or beyond cancer: SUrvivors' Rehabilitation Evaluation after CANcer (SURECAN) trial. Trials. 2024. PMID: 38566197. doi:10.1186/s13063-024-08062-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。